144 related articles for article (PubMed ID: 28649657)
1. Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer.
Solzak JP; Atale RV; Hancock BA; Sinn AL; Pollok KE; Jones DR; Radovich M
NPJ Breast Cancer; 2017; 3():17. PubMed ID: 28649657
[TBL] [Abstract][Full Text] [Related]
2. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
3. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
4. Does the PI3K pathway play a role in basal breast cancer?
Moulder SL
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S66-71. PubMed ID: 21115424
[TBL] [Abstract][Full Text] [Related]
5. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
7. PI3K Inhibitors in Breast Cancer Therapy.
Ellis H; Ma CX
Curr Oncol Rep; 2019 Dec; 21(12):110. PubMed ID: 31828441
[TBL] [Abstract][Full Text] [Related]
8. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Martín M; Chan A; Dirix L; O'Shaughnessy J; Hegg R; Manikhas A; Shtivelband M; Krivorotko P; Batista López N; Campone M; Ruiz Borrego M; Khan QJ; Beck JT; Ramos Vázquez M; Urban P; Goteti S; Di Tomaso E; Massacesi C; Delaloge S
Ann Oncol; 2017 Feb; 28(2):313-320. PubMed ID: 27803006
[TBL] [Abstract][Full Text] [Related]
9. Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.
Criscitiello C; Viale G; Curigliano G; Goldhirsch A
Breast Cancer (Dove Med Press); 2018; 10():23-29. PubMed ID: 29430197
[TBL] [Abstract][Full Text] [Related]
10. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
[TBL] [Abstract][Full Text] [Related]
11. Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor.
Ahmed K; Koval A; Xu J; Bodmer A; Katanaev VL
Cancer Lett; 2019 May; 449():45-55. PubMed ID: 30771433
[TBL] [Abstract][Full Text] [Related]
12. Targeting the androgen receptor in triple-negative breast cancer.
Gucalp A; Traina TA
Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
[TBL] [Abstract][Full Text] [Related]
13. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
Choi C; Kwon J; Lim S; Helfman DM
Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
[TBL] [Abstract][Full Text] [Related]
14. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
[TBL] [Abstract][Full Text] [Related]
15. Application of a Biphasic Mathematical Model of Cancer Cell Drug Response for Formulating Potent and Synergistic Targeted Drug Combinations to Triple Negative Breast Cancer Cells.
Shen J; Li L; Howlett NG; Cohen PS; Sun G
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32349331
[TBL] [Abstract][Full Text] [Related]
16. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
Gul A; Leyland-Jones B; Dey N; De P
Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
[TBL] [Abstract][Full Text] [Related]
17. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
18. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Geuna E; Milani A; Martinello R; Aversa C; Valabrega G; Scaltriti M; Montemurro F
Expert Opin Investig Drugs; 2015 Mar; 24(3):421-31. PubMed ID: 25645727
[TBL] [Abstract][Full Text] [Related]
19. PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Rajput S; Guo Z; Li S; Ma CX
Oncotarget; 2019 Jun; 10(38):3667-3680. PubMed ID: 31217901
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
